title: Novel targets for inflammatory bowel disease therapeutics.
abstract: In recent years, many new agents have been evaluated for the treatment of inflammatory bowel disease. In this paper, we critically review recently published literature about these novel therapies, which have been the result of extensive research identifying molecular targets. Of the various biologicals and small molecules that have recently been tested in clinical trials, several demonstrated clinical efficacy with a tolerable safety profile. We discuss a number of them with specific focus on vedolizumab, a monoclonal antibody directed against the alpha4beta7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, a small molecule targeting Janus-activated kinase. Most likely, these three agents will find their way to the market and offer significant therapeutic alternatives for the management of Crohn's disease and/or ulcerative colitis.
authors: Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. g.dhaens@amc.uva.nl
authors: Mark
authors: M
authors: Löwenberg
authors: Geert
authors: G
authors: D'Haens
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D000068582:Certolizumab Pegol; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D000069285:Infliximab; D000069442:Natalizumab; D010880:Piperidines / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D007140:Immunoglobulin Fab Fragments; D000069442:Natalizumab; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D015363:Quinolones; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; C479163:tofacitinib; C476223:laquinimod; C529000:golimumab; C543529:vedolizumab; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068582:Certolizumab Pegol